推荐产品
生物源
mouse
共軛
FITC conjugate
抗體表格
purified from hybridoma cell culture
抗體產品種類
secondary antibodies
無性繁殖
HP-6017, monoclonal
形狀
buffered aqueous solution
物種活性
rabbit, sheep, horse (IgG), goat, human
儲存條件
protect from light
技術
dot immunobinding: 1:16
particle immunofluorescence: 1:16
同型
IgG2a
運輸包裝
dry ice
儲存溫度
−20°C
目標翻譯後修改
unmodified
正在寻找类似产品? 访问 产品对比指南
一般說明
Monoclonal Anti-Human IgG (mouse IgG2a isotype) is derived from the hybridoma produced by the fusion of mouse myeloma cells and splenocytes from an immunized mouse. Immunoglobulins (Igs) belongs immunoglobulin super-family. Each immunoglobin have two heavy (H) and two light (L), held together by disulphide linkages. The light comprises of one variable N-terminal region and a constant C-terminal region. The heavy chain has one variable N-terminal region and three or four constant (CH1-CH4) C-terminal region.
特異性
该抗体对人 IgG 的 Fc 部分具有特异性,并识别所有人 IgG 亚类共有的表位。在 IUIS/WHO 研究中,该抗体被用作 Fc 特异性试剂。
應用
Monoclonal Anti-Human IgG (Fc specific)-FITC antibody produced in mouse has been used in:
- Fluorescent Dot Immunobinding Assay (F-DIBA)
- Particle Immunofluorescent Assay (F-IFMA)
- flow cytometry
生化/生理作用
Digestion of IgG by papain results in generation of fragment antigen binding (Fab) comprising one complete L chain and a variable and CH1 region of H chain. Pepsin digestion of IgG results in fragment crystallisable (fc), containing the H chain constant region. IgG antibody have enormous therapeutic potential and the Fc is for the development of therapeutic antibody. Although the antibody site is located in the terminal end of the human IgG molecule (part of the Fab fragment), the Fc portion has various important functions such as complement fixation, site for rheumatoid factor (autoantibodies directed to Fc), passage through placental membrane and staphylococcus protein A binding.
外觀
Solution in 0.01 M phosphate buffer pH 8.0, containing 1% inactivated bovine serum albumin and 15 mM sodium azide.
免責聲明
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Not finding the right product?
Try our 产品选型工具.
訊號詞
Danger
危險聲明
危險分類
Resp. Sens. 1 - Skin Sens. 1
儲存類別代碼
12 - Non Combustible Liquids
水污染物質分類(WGK)
WGK 3
閃點(°F)
Not applicable
閃點(°C)
Not applicable
其他客户在看
A nonviral carrier for targeted gene delivery to tumor cells
Cancer Gene Therapy, 11(2), 156-156 (2004)
Pharmaceutics, 14(7) (2022-07-28)
Immuno-positron emission tomography (PET) has great potential to evaluate the target expression level and therapeutic response for targeted cancer therapy. Immuno-PET imaging with pertuzumab, due to specific recognition in different binding sites of HER2, could be useful for the determination
European journal of nuclear medicine and molecular imaging, 44(8), 1328-1336 (2017-03-21)
c-MET and its ligand hepatocyte growth factor are often dysregulated in human cancers. Dynamic changes in c-MET expression occur and might predict drug efficacy or emergence of resistance. Noninvasive visualization of c-MET dynamics could therefore potentially guide c-MET-directed therapies. We
Development and characterization of clinical-grade 89Zr-trastuzumab for HER2/neu immunoPET imaging
Journal of Nuclear Medicine, 50(6), 974-981 (2009)
Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 50(6), 974-981 (2009-05-16)
The anti-human epidermal growth factor receptor 2 (HER2/neu) antibody trastuzumab is administered to patients with HER2/neu-overexpressing breast cancer. Whole-body noninvasive HER2/neu scintigraphy could help to assess and quantify the HER2/neu expression of all lesions, including nonaccessible metastases. The aims of
我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门